Indeed, LDLR silencing potentiates tumor regression induced by chemotherapy.14 Finally, pharmacological inhibitors of SOAT1 enzyme (avasimibe, Sandoz 58-035) (Table 1), through limiting cholesteryl ester storage, have been shown to suppress tumor growth in prostate cancer xenograft models.13 Here, LDLR is linked to neoplasm.